ANI Pharmaceuticals (NASDAQ:ANIP) Lowered to “Sell” Rating by StockNews.com

StockNews.com lowered shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a sell rating in a research note released on Tuesday morning.

Several other research firms have also recently commented on ANIP. HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Guggenheim raised their price objective on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective for the company. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Finally, Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They set a “buy” rating and a $80.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.75.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $65.12 on Tuesday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -118.40 and a beta of 0.49. The company’s fifty day simple moving average is $62.15 and its 200 day simple moving average is $59.00. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $70.00.

Insider Activity

In related news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares of the company’s stock, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares of the company’s stock, valued at $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,200 shares of company stock worth $191,776 over the last three months. 12.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently bought and sold shares of ANIP. US Bancorp DE grew its stake in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after acquiring an additional 531 shares in the last quarter. KBC Group NV boosted its holdings in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in ANI Pharmaceuticals in the 4th quarter worth about $166,000. Rafferty Asset Management LLC purchased a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $200,000. Finally, Bridgefront Capital LLC purchased a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $204,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.